ESET Research uncovers variants of AsyncRAT, popular choice of cybercriminals 
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease 
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi’s Desert Dragons facilities Zymergen Announces Pricing of Upsized Initial Public Offering
EMERYVILLE, Calif., April 21, 2021 (GLOBE NEWSWIRE) — Zymergen Inc. (“Zymergen”), one of the world’s…
Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA
PRESS RELEASE April 22, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on…
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination…
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical…
PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics
PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and…
Freeline to Participate in Upcoming Investor Conferences in April and May 2021
LONDON, April 21, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company”…
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at Upcoming Scientific Conferences
ASGCT and ISCT abstracts highlight the Company’s progress with gene circuit-engineered allogeneic CAR-NK cell therapy…
MDxHealth announces listing of 9,639,489 existing shares on Euronext Brussels following the January 2021 Capital Increase
NEWS RELEASE – REGULATED INFORMATION 21 April 2021, 10:00 p.m. CET IRVINE, CA, and HERSTAL, BELGIUM –…
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Basel, Switzerland, April 21, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved…
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the…
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination…
22nd Century Group Issues Annual Letter to Shareholders
Company’s Confidence in MRTP Authorization is High; Launch of VLN® is Only the Beginning for…
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide
Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase…
Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET
WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer
TORONTO and HOUSTON, April 21, 2021 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the…
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical…
Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced…
Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma…
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
– 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference…
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization
Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the…